Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

155
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

8.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Roles of miR-200 family members in lung cancer: more than tumor suppressors.

Future oncology (London, England)·2018
Same author

Alterations and structural resilience of the gut microbiota under dietary fat perturbations.

The Journal of nutritional biochemistry·2018
Same author

Development and Feasibility Testing of an mHealth (Text Message and WeChat) Intervention to Improve the Medication Adherence and Quality of Life of People Living with HIV in China: Pilot Randomized Controlled Trial.

JMIR mHealth and uHealth·2018
Same author

Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury.

Frontiers in immunology·2018
Same author

Corrigendum to: The calcium sensor TaCBL4 and its interacting protein TaCIPK5 are required for wheat resistance to stripe rust fungus.

Journal of experimental botany·2018
Same author

Transcriptome analysis of Valsa mali reveals its response mechanism to the biocontrol actinomycete Saccharothrix yanglingensis Hhs.015.

BMC microbiology·2018
Same journal

Response to Commentary: Memory B Cells in Major Depressive Disorder: Toward Mechanistic and Clinical Refinement.

Current medical science·2026
Same journal

Real-World Analysis of Organ Transplantation-Specific Agent Based on Large Language Model in Post-Transplant Self-Management During Off-Hours: A Mixed-Methods Study.

Current medical science·2026
Same journal

Memory B Cells in Major Depressive Disorder: Toward Mechanistic and Clinical Refinement.

Current medical science·2026
Same journal

Timing and Location are Keys: ERCP Success and Its Benefit in MPD Injury after Acute Pancreatitis.

Current medical science·2026
Same journal

Global Burden of Peptic Ulcer Disease (1990-2021) and Projections to 2050: A Comprehensive Analysis of Age, Sex, and Socioeconomic Disparities.

Current medical science·2026
Same journal

Bone Morphogenetic Proteins in Obesity Management: Therapeutic Potential and Challenges Beyond the Skeleton.

Current medical science·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

5.5K

Multi-Scale Genetic and Transcriptomic Analyses Identify Druggable Targets for Epilepsy.

Gao-Yang Zhong1, Cong Liu1, Hui-Ling Wang2

  • 1Department of Forensic Medicine, Huazhong University of Science and Technology, Wuhan, 430030, China.

Current Medical Science
|April 21, 2026
PubMed
Summary
This summary is machine-generated.

This study identifies seven epilepsy causal genes, including FGFR3 and HAGH, and reveals FGFR3-driven FGF signaling as a key molecular pathway. These findings offer new therapeutic targets for epilepsy treatment.

Keywords:
FGFR3HAGHEpilepsyExpression Quantitative Trait Loci (eQTL)Genome-wide association study (GWAS)Single-cell RNA sequencing (scRNA-seq)

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.5K

Related Experiment Videos

Last Updated: Apr 23, 2026

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

5.5K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.5K

Area of Science:

  • Genomics
  • Neuroscience
  • Systems Biology

Background:

  • Epilepsy affects 70 million worldwide, presenting high genetic heterogeneity.
  • Previous studies combined Genome-Wide Association Studies (GWAS) with bulk expression quantitative trait loci (eQTLs) but lacked cellular context.
  • Understanding the cellular basis of genetic regulation in epilepsy is crucial.

Purpose of the Study:

  • To identify causal epilepsy genes by integrating multi-omics data.
  • To define the cellular context and cell-type specificity of genetic regulation in epilepsy.
  • To discover potential therapeutic targets and compounds for epilepsy treatment.

Main Methods:

  • Integrated epilepsy GWAS data with brain bulk and single-cell eQTLs using SMR and Bayesian colocalization.
  • Validated identified genes in an independent RNA-seq cohort of refractory epilepsy patients.
  • Characterized cell-type specificity and intercellular signaling via scRNA-seq and CellChat; performed druggability analysis using DSigDB.

Main Results:

  • Identified seven epilepsy causal genes: FGFR3, PM20D1, ZNF564, HAGH, CAPN15, CCDC117, and DARS1-AS1.
  • FGFR3 and HAGH were identified as druggable targets, with FGFR3 predominantly in astrocytes and HAGH in neurons.
  • FGFR inhibitor Ro-4396686 emerged as a top drug-repurposing candidate.

Conclusions:

  • Multi-scale data integration revealed epilepsy genetic variants and FGFR3-driven FGF signaling as a key molecular axis.
  • The study elucidates the cellular context of epilepsy genetic regulation.
  • FGFR3 and HAGH are highlighted as promising therapeutic targets for epilepsy.